AGRX - Agile Therapeutics GAAP EPS of -$3.78 beats by $2.22 revenue of $1.76M beats by $0.54M

Agile Therapeutics press release (NASDAQ:AGRX): Q1 GAAP EPS of -$3.78 beats by $2.22. Revenue of $1.76M (+1366.7% Y/Y) beats by $0.54M. Shares +4.85%. “We produced another quarter of double-digit growth in key prescription data for Twirla while also increasing revenue and reducing cash burn,” said Agile Therapeutics Chairman and Chief Executive Officer Al Altomari. “ Based on the prescription data trends we are seeing so far in the second quarter and the advancement of our Twirla business plan, we currently expect to report a fourth consecutive quarter of strong demand growth for the second quarter 2022 and provide further confidence that our business plan is delivering.”

For further details see:

Agile Therapeutics GAAP EPS of -$3.78 beats by $2.22, revenue of $1.76M beats by $0.54M